Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Active, not recruiting · Phase 1 · NCT05595460
Conditions: SCLC,Extensive Stage
At a glance
- Research payments reported, 2025
- $1.4M
- U.S. investigators named
- 16
- Sites paid
- 15
- Planned or actual enrollment
- 21
About the trial
- Sponsor
- RayzeBio, Inc.
- Tested
- RYZ101 Dose Level 1 (drug), RYZ101 Dose Level 2 (drug), RYZ101 Dose Level 3 (drug), RYZ101 Dose Level -1 (drug), Atezolizumab (drug), Carboplatin (drug), Etoposide (drug)
- Dates
- Started 2022-10-10; completion 2027-07
- Results posted
- Not yet
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1.4M in research payments for this study in 2025 (15 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jonathan W. Goldman, M.D. Hematology & Oncology · Santa Monica, CA
- Claire K. Mulvey, M.D. Hematology & Oncology · San Francisco, CA
- Ephraim E. Parent, MD Nuclear Medicine · Jacksonville, FL
- Justin M. Rineer, MD Radiation Oncology · Orlando, FL
- Estelamari Rodriguez, MD Hematology & Oncology · Miami, FL
- David L. Bushnell JR., MD Nuclear Medicine · Iowa City, IA
- Zhonglin Hao, MD, PHD Medical Oncology · Lexington, KY
- Krisha J. Howell, M.D. Radiation Oncology · Troy, MI
- Manish K. Thakur, MD Medical Oncology · Grand Rapids, MI
- Aaron S. Mansfield, MD Medical Oncology · Rochester, MN
- Clifford G. Robinson, MD Radiation Oncology · Saint Louis, MO
- Robert M. Langdon, M.D. Hematology & Oncology · Omaha, NE
- Noridza Rivera-rodriguez Hematology & Oncology · San Juan, PR
- Umang Patel, M.D. Radiation Oncology · The Woodlands, TX
- Wallace L. Akerley III, MD Medical Oncology · Salt Lake City, UT
- Heloisa P. Soares, M.D. Hematology & Oncology · Salt Lake City, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic Jacksonville $406,207
- Mayo Clinic Sports Medicine $260,315
- University of Utah Hospital and Clinics, UT $179,627
- Pan American Center for Oncology Trials Llc $144,200
- University of Iowa Hospital & Clinics, IA $108,778
- Washington University $94,046
- University of Kentucky Research Foundation $59,045
- University of California San Diego $40,614
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $36,602
- Spectrum Health, MI $23,445
- Orlando Health, FL $9,371
- Profound Research Llc $7,280
- Millennium Research & Clinical Development $5,770
- University of Miami $952
- Oncology Hematology West P.c. Dba Nebraska Cancer Specialists $783
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.